S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Stock market today: Asian markets mostly higher after Biden-McCarthy deal on US debt
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
Takeaways on debt ceiling: McCarthy's balancing act, Biden's choice and the challenges ahead
Debt ceiling agreement gets thumbs up from business groups, jeers from some on political right
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Stock market today: Asian markets mostly higher after Biden-McCarthy deal on US debt
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
Takeaways on debt ceiling: McCarthy's balancing act, Biden's choice and the challenges ahead
Debt ceiling agreement gets thumbs up from business groups, jeers from some on political right
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Stock market today: Asian markets mostly higher after Biden-McCarthy deal on US debt
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
Takeaways on debt ceiling: McCarthy's balancing act, Biden's choice and the challenges ahead
Debt ceiling agreement gets thumbs up from business groups, jeers from some on political right
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Stock market today: Asian markets mostly higher after Biden-McCarthy deal on US debt
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
Takeaways on debt ceiling: McCarthy's balancing act, Biden's choice and the challenges ahead
Debt ceiling agreement gets thumbs up from business groups, jeers from some on political right
NASDAQ:VYGR

Voyager Therapeutics (VYGR) Stock Forecast, Price & News

$12.05
+0.11 (+0.92%)
(As of 05/26/2023 08:48 PM ET)
Compare
Today's Range
$11.80
$12.40
50-Day Range
$6.94
$13.85
52-Week Range
$4.61
$14.34
Volume
519,300 shs
Average Volume
466,027 shs
Market Capitalization
$524.66 million
P/E Ratio
5.29
Dividend Yield
N/A
Price Target
$16.00

Voyager Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
32.8% Upside
$16.00 Price Target
Short Interest
Healthy
3.20% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.59
Upright™ Environmental Score
News Sentiment
0.57mentions of Voyager Therapeutics in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$147,684 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From $1.01 to ($1.99) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.72 out of 5 stars

Medical Sector

78th out of 1,012 stocks

Biological Products, Except Diagnostic Industry

11th out of 169 stocks


VYGR stock logo

About Voyager Therapeutics (NASDAQ:VYGR) Stock

Voyager Therapeutics, Inc. is a clinical-stage gene therapy company, which engages in the development of treatments for severe neurological diseases. Its pipeline of gene therapy programs includes VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guang Ping Gao, Mark A. Kay, Krystof Bankiewicz, and Phillip Zamore in June 2013 and is headquartered in Cambridge, MA.

Receive VYGR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Voyager Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

VYGR Stock News Headlines

Small A.I. Firm Wins $2 Billion in Contracts for Breakthrough "Living Software"
Denver firm proves its possible to use AI to save the lives of soldiers in combat. England, Germany, Japan and Australia have all signed contracts within the past 18 months. Get the name of the stock here >>>
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
See More Headlines
Receive VYGR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Voyager Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

VYGR Company Calendar

Last Earnings
3/07/2023
Today
5/28/2023
Next Earnings (Estimated)
8/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VYGR
Fax
N/A
Employees
101
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$16.00
High Stock Price Forecast
$18.00
Low Stock Price Forecast
$14.00
Forecasted Upside/Downside
+32.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-46,410,000.00
Pretax Margin
52.26%

Debt

Sales & Book Value

Annual Sales
$40.91 million
Book Value
$4.98 per share

Miscellaneous

Free Float
33,958,000
Market Cap
$524.66 million
Optionable
Optionable
Beta
1.12

Key Executives

  • Alfred W. Sandrock
    President, Chief Executive Officer & Director
  • Robin Swartz
    Chief Operating Officer
  • Peter P. Pfreundschuh
    Chief Financial & Accounting Officer
  • Todd Carter
    Chief Scientific Officer
  • Julie BurekJulie Burek
    Vice President-Finance













VYGR Stock - Frequently Asked Questions

Should I buy or sell Voyager Therapeutics stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Voyager Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" VYGR shares.
View VYGR analyst ratings
or view top-rated stocks.

What is Voyager Therapeutics' stock price forecast for 2023?

2 analysts have issued twelve-month price targets for Voyager Therapeutics' shares. Their VYGR share price forecasts range from $14.00 to $18.00. On average, they anticipate the company's share price to reach $16.00 in the next twelve months. This suggests a possible upside of 32.8% from the stock's current price.
View analysts price targets for VYGR
or view top-rated stocks among Wall Street analysts.

How have VYGR shares performed in 2023?

Voyager Therapeutics' stock was trading at $6.10 at the beginning of 2023. Since then, VYGR shares have increased by 97.5% and is now trading at $12.05.
View the best growth stocks for 2023 here
.

When is Voyager Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our VYGR earnings forecast
.

How were Voyager Therapeutics' earnings last quarter?

Voyager Therapeutics, Inc. (NASDAQ:VYGR) posted its quarterly earnings data on Tuesday, March, 7th. The company reported ($0.61) earnings per share for the quarter, missing analysts' consensus estimates of ($0.57) by $0.04. The company had revenue of ($1.55) million for the quarter, compared to analysts' expectations of $12.71 million. Voyager Therapeutics had a positive trailing twelve-month return on equity of 95.18% and a negative net margin of 24.21%.

What ETFs hold Voyager Therapeutics' stock?

ETFs with the largest weight of Voyager Therapeutics (NASDAQ:VYGR) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), AdvisorShares Dorsey Wright Micro-Cap ETF (DWMC),

What other stocks do shareholders of Voyager Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Voyager Therapeutics investors own include Micron Technology (MU), REGENXBIO (RGNX), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Amarin (AMRN), CRISPR Therapeutics (CRSP), Inovio Pharmaceuticals (INO), Sangamo Therapeutics (SGMO) and Editas Medicine (EDIT).

What is Voyager Therapeutics' stock symbol?

Voyager Therapeutics trades on the NASDAQ under the ticker symbol "VYGR."

Who are Voyager Therapeutics' major shareholders?

Voyager Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include EcoR1 Capital LLC (8.85%), Armistice Capital LLC (8.09%), Price T Rowe Associates Inc. MD (2.07%), BlackRock Inc. (1.89%), Farallon Capital Management LLC (1.83%) and Acadian Asset Management LLC (1.71%). Insiders that own company stock include Alfred Sandrock, Allison Dorval, Andre Turenne, Ecor1 Capital, Llc, Glenn Pierce, Julie Burek, Neurocrine Biosciences Inc, Omar Khwaja, Robert W Hesslein, Robin Swartz, Rock Ventures Iii LP Third and Todd Alfred Carter.
View institutional ownership trends
.

How do I buy shares of Voyager Therapeutics?

Shares of VYGR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Voyager Therapeutics' stock price today?

One share of VYGR stock can currently be purchased for approximately $12.05.

How much money does Voyager Therapeutics make?

Voyager Therapeutics (NASDAQ:VYGR) has a market capitalization of $524.66 million and generates $40.91 million in revenue each year. The company earns $-46,410,000.00 in net income (profit) each year or $2.28 on an earnings per share basis.

How many employees does Voyager Therapeutics have?

The company employs 101 workers across the globe.

How can I contact Voyager Therapeutics?

Voyager Therapeutics' mailing address is 75 SIDNEY STREET, CAMBRIDGE MA, 02139. The official website for the company is www.voyagertherapeutics.com. The company can be reached via phone at (857) 259-5340 or via email at pcox@vygr.com.

This page (NASDAQ:VYGR) was last updated on 5/29/2023 by MarketBeat.com Staff

My Account -